Roche Holding AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas Schinecker
- Full Time Employees
- 103,249
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Grenzacherstrasse 124 Basel Switzerland 4058
- IPO Date
- Feb 13, 2009
- Website
- roche.com
- Similar Companies
- Business
- Roche Holding AG develops, manufactures and markets pharmaceuticals and in vitro diagnostics worldwide. The company operates through its Pharmaceuticals and Diagnostics divisions; the Pharmaceuticals division offers prescription medicines addressing oncology, immunology, infectious diseases, ophthalmology, neuroscience, cardiovascular, renal and metabolic diseases, haemophilia, inflammatory and respiratory conditions; key products include monoclonal antibodies, antibody-drug conjugates and targeted therapies such as Tecentriq, Perjeta, Avastin, Hemlibra and Actemra; the Diagnostics division provides professional diagnostics systems and reagents for clinical chemistry, immunoassays, molecular diagnostics, tissue diagnostics and diabetes care including Accu-Chek glucose monitoring; additional offerings encompass point-of-care tests such as the recently FDA-cleared Bordetella infection diagnostic and sequencing technologies like those achieving Guinness World Record advances in 2025. Roche Holding AG maintains a global presence with operations in more than 130 countries, substantial manufacturing and R&D facilities in the United States including Genentech as a wholly owned subsidiary and a majority stake in Chugai Pharmaceutical in Japan. Founded in 1896 and headquartered in Basel, Switzerland, the company pursues recent strategic expansions including a USD 50 billion investment over five years announced in 2025 for new US R&D centres in Massachusetts focused on AI and cardiovascular-metabolic research, expanded manufacturing in Indiana for continuous glucose monitoring and weight loss medicines, gene therapy facilities in Pennsylvania and upgrades across multiple states creating over 12,000 jobs; it entered a definitive merger agreement in September 2025 to acquire 89bio for up to USD 3.5 billion to bolster its CVRM portfolio with pegozafermin for moderate to severe MASH; other moves encompass the 2024 acquisition of Carmot Therapeutics for USD 2.7 billion, 2023 purchase of Televant Holdings for USD 7.1 billion, partnerships like the antibody-drug conjugate deal with Innovent Biologics and licensing of CDK inhibitors from Regor Pharmaceuticals.
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
Olema: The Market Overreacted To Roche's SERD Failure
Isomorphic Labs' $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
Roche gets second European approval for Alzheimer's test
Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools
Switzerland's Roche agrees to acquire US-based PathAI
Roche: Policy Overhang Clears, Fundamentals Intact, Upside Remains Limited But Positive
Iran won't give up its “new nuclear weapon” - the Strait of Hormuz: David Roche
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
Roche Backs Full-Year View as Quarterly Sales Rise
Roche Q1 sales down on forex effects
Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deaths
Roche launches new Elevidys study after feedback from European regulator
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion
HNL Lab Medicine Celebrates Preferred Partnership With Roche Diagnostics
Roche (OTCMKTS:RHHVF) Trading 0.4% Higher – Here’s What Happened